{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:19:31Z","timestamp":1770283171081,"version":"3.49.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1001\/jamaophthalmol.2020.2309","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T15:02:03Z","timestamp":1594306923000},"page":"835","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"138","author":[{"given":"Timothy L.","family":"Jackson","sequence":"first","affiliation":[{"name":"Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom"},{"name":"Department of Ophthalmology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Soare","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Petrarca","sequence":"additional","affiliation":[{"name":"Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Simpson","sequence":"additional","affiliation":[{"name":"Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom"},{"name":"Department of Ophthalmology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Neffendorf","sequence":"additional","affiliation":[{"name":"Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom"},{"name":"Department of Ophthalmology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Petrarca","sequence":"additional","affiliation":[{"name":"Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom"},{"name":"Department of Ophthalmology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"Muldrew","sequence":"additional","affiliation":[{"name":"NetwORC UK, Central Angiographic Reading Center, Queen\u2019s University of Belfast, Belfast, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[{"name":"Reading Center, Moorfields Eye Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[{"name":"NetwORC UK, Central Angiographic Reading Center, Queen\u2019s University of Belfast, Belfast, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Membrey","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Maidstone Hospital, Maidstone, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bristol Eye Hospital, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Costen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hull and East Yorkshire Eye Hospital, Hull, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Steel","sequence":"additional","affiliation":[{"name":"Vitreoretinal Unit, Sunderland Eye Infirmary, Sunderland, United Kingdom"},{"name":"Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riti","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the MERLOT Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"eoi200048r1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/bjophthalmol-2011-301109","article-title":"The estimated prevalence and incidence of late stage age related macular degeneration in the UK.","volume":"96","author":"Owen","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi200048r2","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"14","key":"eoi200048r3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"eoi200048r4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi200048r5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","article-title":"Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme.","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"eoi200048r6","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-related Macular Degeneration Treatments Trials.","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi200048r7","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi200048r8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92?976 ranibizumab injections: report 1: visual acuity.","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi200048r9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bjo.77.5.265","article-title":"Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study.","volume":"77","author":"Chakravarthy","year":"1993","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi200048r10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.eye.6700306","article-title":"Beta irradiation: new uses for an old treatment: a review.","volume":"17","author":"Kirwan","year":"2003","journal-title":"Eye (Lond)"},{"issue":"7","key":"eoi200048r11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.ophtha.2012.01.014","article-title":"Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.","volume":"119","author":"Dugel","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi200048r12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/IAE.0000000000000026","article-title":"Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results.","volume":"34","author":"Petrarca","year":"2014","journal-title":"Retina"},{"issue":"6","key":"eoi200048r13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2016.02.028","article-title":"Epimacular brachytherapy for previously treated neovascular age-related macular degeneration (MERLOT): a phase 3 randomized controlled trial.","volume":"123","author":"Jackson","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi200048r14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ophtha.2012.07.068","article-title":"Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).","volume":"120","author":"Dugel","year":"2013","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi200048r15","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.ophtha.2013.01.074","article-title":"Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.","volume":"120","author":"Jackson","year":"2013","journal-title":"Ophthalmology"},{"issue":"20","key":"eoi200048r16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"9","key":"eoi200048r18","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.ophtha.2013.02.016","article-title":"Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.","volume":"120","author":"Jackson","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200048r19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ophtha.2014.07.043","article-title":"Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study.","volume":"122","author":"Jackson","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi200048r20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/IAE.0000000000000283","article-title":"Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response.","volume":"35","author":"Jackson","year":"2015","journal-title":"Retina"},{"issue":"5","key":"eoi200048r21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/eye.2013.12","article-title":"United Kingdom National Ophthalmology Database Study of Vitreoretinal Surgery: report 1; case mix, complications, and cataract.","volume":"27","author":"Jackson","year":"2013","journal-title":"Eye (Lond)"},{"issue":"9","key":"eoi200048r22","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1167\/iovs.12-10164","article-title":"Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.","volume":"53","author":"Kakinoki","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"eoi200048r23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10792-020-01581-4","article-title":"Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema.","volume":"38","author":"Chen","year":"2018","journal-title":"Int Ophthalmol"},{"issue":"1","key":"eoi200048r24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s13063-016-1676-7","article-title":"StereoTactic radiotherapy for wet age-related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.","volume":"17","author":"Neffendorf","year":"2016","journal-title":"Trials"},{"issue":"6921","key":"eoi200048r25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2013I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019 Collaboration.","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"BMJ"},{"key":"eoi200048r17","unstructured":"MedDRA. Welcome to the ICH MedDRA website. Accessed June 1, 2020. https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2768081\/jamaophthalmology_jackson_2020_oi_200048_1597179663.87583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T02:26:05Z","timestamp":1616552765000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2768081"}},"subtitle":["The MERLOT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2309","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}